# A Study on the Treatment of CTIT of the Efficacy and Safety With Romiplostim N01 Compared to Recombinant Human Interleukin-11

> **NCT06759636** · PHASE3 · RECRUITING · sponsor: **The First Affiliated Hospital with Nanjing Medical University** · enrollment: 88 (estimated)

## Conditions studied

- CTIT: Cancer Therapy Induced Thrombocytopenia

## Interventions

- **DRUG:** Romiplostim N01
- **DRUG:** Recombinant Human Interleukin-11 (rhIL-11)

## Key facts

- **NCT ID:** NCT06759636
- **Lead sponsor:** The First Affiliated Hospital with Nanjing Medical University
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-02-24
- **Primary completion:** 2026-04-21
- **Final completion:** 2026-07-21
- **Target enrollment:** 88 (ESTIMATED)
- **Last updated:** 2026-04-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06759636

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06759636, "A Study on the Treatment of CTIT of the Efficacy and Safety With Romiplostim N01 Compared to Recombinant Human Interleukin-11". Retrieved via AI Analytics 2026-06-14 from https://api.ai-analytics.org/clinical/NCT06759636. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*